Harvard Bioscience, Inc. — FY2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017. This is an annual report, not a standalone fourth-quarter filing. The company develops and sells life-science research instruments, systems, and supplies globally; no customer represented more than 10% of revenue.
Financial performance and liquidity
| Metric | FY2017 | FY2016 |
|---|---|---|
| Revenue | $101.9 million | $104.5 million |
| Gross profit / margin | $47.6 million / 46.7% | $48.4 million / 46.3% |
| Operating loss | $0.1 million | $3.0 million |
| Net loss | $0.9 million | $4.3 million |
| Loss per share, basic and diluted | $0.02 | $0.13 |
| Cash from operating activities | $1.1 million | $5.4 million |
| Cash and cash equivalents at year-end | $5.7 million | $5.6 million |
| Working capital at year-end | $33.5 million | $30.9 million |
| Debt at year-end, net of financing costs | $11.7 million | $13.7 million |
| Stockholders’ equity at year-end | $80.9 million | $72.2 million |
FY2017 revenue fell 2.6%. Management attributed about $2.1 million of the decrease to the 2016 AHN divestiture and $0.3 million to currency translation; excluding those effects, organic revenue declined approximately 0.2%. Operating expenses declined to $47.7 million from $51.4 million. The net loss narrowed, with a $1.2 million income tax benefit in 2017 versus $1.2 million tax expense in 2016. Fourth-quarter 2017 net income was $1.0 million, including a $1.2 million tax benefit.
Operating cash flow decreased substantially year over year, primarily because of working-capital outflows and higher noncash adjustments in the prior-year comparison. Capital expenditures were $0.9 million. At year-end, debt less cash was approximately $6.0 million. Cash held by foreign subsidiaries was $4.8 million and was not available for U.S. operations unless repatriated.
Material changes, outlook, and risks
- Portfolio changes after year-end: In January 2018, the company sold substantially all Denville assets for approximately $20 million, including a contingent $3 million earn-out; it received $17 million at closing. It also acquired Data Sciences International (DSI) for approximately $70 million.
- Financing and leverage: The Denville proceeds repaid approximately $11.9 million of prior debt. The company then entered into secured facilities comprising a $64 million term loan and up to a $25 million revolver to help fund DSI and related costs. As of March 16, 2018, borrowings under the new agreement were reported at $67 million. The facilities have restrictive covenants, collateralize substantially all assets, and carry variable-rate exposure; the company entered into a swap fixing LIBOR at 2.72% on a portion of the term loan.
- Management outlook: No quantified revenue or earnings guidance is provided. Management expected cash, operating cash generation, and debt capacity to support operations and capital needs for at least the next 12 months, while noting that additional debt or equity financing may be needed.
- Key risks: Dependence on academic and government research budgets; competition and technology shifts; international, currency, and Brexit exposure; acquisition integration and realization of DSI synergies; increased debt service and covenant compliance; and uncertain effects of U.S. tax reform. The company also disclosed an early-stage wrongful-death lawsuit related to products of former subsidiary Biostage; damages sought were unspecified, and the outcome could not be predicted.
- Other notable disclosures: The 2017 tax benefit includes provisional Tax Act accounting; related estimates could change. The company reported that 2016 material weaknesses in income-tax and inventory controls were remediated in the fourth quarter of 2017. Management and the auditor concluded internal control over financial reporting was effective at year-end. The financial statements received an unqualified audit opinion.
Investor verification priorities
- Review post-year-end DSI acquisition funding, actual debt outstanding, interest costs, covenants, and available revolver capacity.
- Track DSI integration, acquired-business results, and whether expected revenue and cost synergies materialize.
- Verify the Denville earn-out conditions and collection of the contingent $3 million consideration.
- Assess underlying organic revenue trends, gross-margin mix, working-capital movements, and operating cash conversion.
- Monitor final Tax Act accounting, deferred-tax asset valuation allowances, and the outcome and insurance coverage of the Biostage-related litigation.